{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'The Simplification to Atazanavir/Ritonavir+Lamivudine as Maintenance Therapy', '(SALT) study [Perez-Molina, 2015] was a 96-week multicenter, randomized, open-label,', 'clinical trial that compared atazanavir/ritonavir (ATV/r) + 3TC with ATV/r + 2NRTIs', '(selected at the discretion of the investigator) in 286 people living with HIV on a stable 3-', 'drug regimen who switch therapy because of toxicity, intolerance, or simplification. The', 'primary endpoint was to evaluate the non-inferior efficacy of maintenance therapy with', 'ATV/r + 3TC compared to ATV/r + 2 NRTIs at 48 weeks (noninferiority margin, - -12%)', 'using the time to loss of virologic response (TLOVR) algorithm. At 48 weeks, 78.4% of', 'participants receiving triple therapy VS. 83.6% of participants switched to 2-drug therapy', 'had maintained HIV-RNA levels <50 c/mL thus establishing non-inferiority between', 'these two treatment arms (difference between the arms 5.2; -4.8 to 15.2). Treatment', 'discontinuations (2%) were less frequent in the 2-drug therapy group (vs 7% in the triple', 'therapy group).', 'An INSTI-containing oral 2-drug regimen, cabotegravir (CAB) + rilpivirine (RPV), was', 'evaluated as a maintenance therapy in people living with HIV who had virologic', 'suppression after 24 weeks of 3-drug ART [Margolis, 2015]. The CAB + RPV arms', 'showed comparative antiviral efficacy as the efavirenz (EFV) + 2 NRTIs arm. Following', '72 weeks of two-drug maintenance therapy (Week 96), in the ITT maintenance = exposed', 'population, 86% of CAB + RPV participants and 83% of EFV + 2 NRTIs participants', 'remained virologically suppressed. Virologic failure was seen in 4% of the CAB arm and', '2% of the EFV+2 NRTI arm.', 'The SWORD-1 and SWORD-2 studies [Llibre, 2017] are ongoing 148-week open-label,', 'multicenter Phase III, non-inferiority studies evaluating the efficacy and safety of', 'switching from a 3 or 4-drug current antiretroviral regimen (CAR) to DTG + RPV in', '1024 participants. The primary endpoint was the proportion of participants with plasma', 'HIV-RNA levels <50 c/mL at Week 48. Switching to DTG + RPV was found to be non-', 'inferior to continuing CAR in pooled analysis of both the intent-to-treat exposed (ITT-E)', 'population [95% VS. 95%; difference: -0.2% (95% CI: -3.0%, 2.5%)] and the per-protocol', 'population [96% VS. 96%; difference: -0.7% (95% CI: -3.3%, 1.8%)]. For the pooled', 'studies, 23% and 21% of participants were female in the DTG +RPV and CAR arms,', 'respectively. Efficacy remained high in the female subgroup (93% vs. 91%). At Week', '100 in the Early Switch group, 456 (89%) had VL < 50c/mL; low rate of snapshot', 'virologic non-response was observed (3%); 6 (1.2%) participants met Confirmed', 'Virologic Withdrawal (CVW) criterion. One participant with RPV resistance at CVW', '(Early Switch group, Wk100) had pre-existing NNRTI mutations at baseline. No', 'participants developed INSTI resistance [Aboud, 2018].', '2.3.', 'Benefit/Risk Assessment', 'More detailed information about the known and expected benefits and risks and', 'reasonably expected adverse events of DTG or 3TC may be found in the most recent', \"version of the Investigator's Brochure (IB) and any IB supplements and the product\", 'labels.', 'The following section outlines the risk assessment and mitigation strategy for DTG and', '3TC in this protocol. For CAR, the approved country product labels for the respective', 'drugs should be referenced.', '25']['2017N331008_06', 'CONFIDENTIAL', '208090', '2.3.1.', 'Risk Assessment', 'The following table outlines the risk assessment and mitigation strategy for this protocol.', 'Potential Risk of', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Clinical Significance', 'Investigational Product (IP) [DTG and 3TC]', 'Refer to Investigator Brochures (IBs) for additional information', 'DTG: Hypersensitivity', 'DTG: HSR has been observed uncommonly with DTG. Rash was', 'Participants with history of allergy/sensitivity to any of the study', 'reaction (HSR) and', 'commonly reported in DTG Phase llb/III clinical trials; episodes', 'interventions are excluded.', 'rash', 'were generally mild to moderate in intensity; no episodes of severe', 'rash, such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal', 'Specific/detailed toxicity management guidance is provided for rash', 'Necrolysis (TEN) and erythema multiforme were reported.', '(Section 11.3.1.6).', 'The participant informed consent form (ICF) includes information on', 'this risk and the actions participants should take in the event of a', 'HSR or associated signs and symptoms', 'DTG: Drug induced', 'DTG: Non-clinical data suggested a possible, albeit low, risk for', 'Participants meeting any of the following criteria during the', 'liver injury (DILI) and', 'hepatobiliary toxicity with DTG. Drug-related hepatitis is considered', 'screening period are excluded from participating.', 'other clinically', 'an uncommon risk for ART containing DTG regardless of dose or', 'Alanine aminotransferase (ALT) >5 times the upper limit of', 'significant liver', 'treatment population. For participants with hepatitis B virus (HBV)', 'normal (ULN) or ALT >3xULN and bilirubin >1.5x ULN (with', 'chemistry elevations', 'and/or hepatitis C virus (HCV) co-infection, improvements in', '>35% direct bilirubin)', 'immunosuppression as a result of HIV virologic and immunologic', 'Participants positive for Hepatitis B surface antigen (+HBsAg)', 'responses to DTG- containing ART, along with inadequate therapy', 'Participants negative for HBsAg and anti-HBsAg and positive for', 'for HBV co-infected participants, likely contributed to significant', 'anti-HBc and HBV DNA', 'elevations in liver chemistries. A review of postmarketing data', 'Anticipated need for any hepatitis C virus (HCV) therapy during', 'found that the number of cases reporting particularly severe liver', 'the randomized phase of the study, or anticipated need for HCV', '3TC: Use in HBV co-', 'dysfunction was found to be very low in the context of exposure to', 'therapy with a potential for adverse drug-drug interactions with', 'DTG and DTG/ABC/3TC. The reported cases of severe liver', 'DTG or 3TC', 'infected participants', 'dysfunction (including acute hepatic failure) are complex with', 'Specific/detailed liver stopping criteria and toxicity management', 'and emergence of HBV', 'potential confounding factors but in a very small number of cases,', 'guidance is provided for suspected DILI or other clinically significant', 'variants resistant to', '3TC', 'drug-induced liver injury is likely and the role of DTG containing', 'liver chemistry elevations (Section 11.9).', 'regimens cannot be ruled out particularly in those involving DTG', '26']\n\n###\n\n", "completion": "END"}